CPI, one of the founding partners in the Medicines Manufacturing Innovation Centre, has announced the signing of an agreement with PwC, making the company the latest partner in the collaborative effort. The Centre (established via a partnership among CPI, the University of Strathclyde, UK Research and Innovation, Scottish Enterprise and founding industry partners AstraZeneca and GSK) seeks to promote more innovative drug manufacturing processes and enable a more agile supply chain.
PwC and the existing partners will work to maximize technological opportunities across the pharma supply chain. Efforts include the organization’s flagship Grand Challenge projects, intended to advance emergent and disruptive technologies. The program is partially funded by Innovate UK through the Industrial Strategy Challenge Fund and Scottish Enterprise via the Scottish Government.
According to the Centre, PwC will contribute via increased opportunities for business development, leveraged through its global connections and brand authority. Company representatives also are expected to evaluate the marketplace for future technologies, seeking out disruptive innovations, organizations and opportunities; and to seek out funding from private investors, industry and government.
Johnathon Marshall, UK Pharma and Life Science Consulting lead at PwC, said, “We are excited to join the team at the Medicines Manufacturing Innovation Centre – bringing PwC’s insights, experiences and connections. We are confident that this collaboration will have a big impact on the future of pharmaceutical manufacturing.”
Scott Lawson, a Glasgow-based director at PwC, added: “The planned new facility in Renfrewshire is befitting of the strength and depth of the pharma and life sciences capabilities here in Scotland. We have a highly skilled team within our pharma and life sciences industry group, and we’re really excited to be embarking on this partnership with the Medicines Manufacturing Innovation Centre.”
Dave Tudor, managing director of the Medicines Manufacturing Innovation Centre, and Biologics and Quality at CPI, said, “By partnering with PwC, the Medicines Manufacturing Innovation Centre will be able to work smarter, better and faster, ensuring more value to patients and the economy while advancing the UK’s already strong medicines manufacturing industry even further.”
Neil Sheddan, Business Development Director at the Medicines Manufacturing Innovation Centre at CPI, said, “This partnership will support the Medicines Manufacturing Innovation Centre to reach new innovative organizations and markets, leading to more opportunities for industry to collaborate on next-generation technology.”